---
title: "Kymera Therapeutics Doses First Patient in Phase 2b Asthma Trial of KT-621"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274145169.md"
datetime: "2026-01-29T12:00:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274145169.md)
  - [en](https://longbridge.com/en/news/274145169.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274145169.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274145169.md) | [English](https://longbridge.com/en/news/274145169.md)


# Kymera Therapeutics Doses First Patient in Phase 2b Asthma Trial of KT-621

Kymera Therapeutics Inc. has announced the initiation of dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, a first-in-class oral STAT6 degrader, in patients with moderate to severe eosinophilic asthma. The company expects to report data from the BREADTH trial in late 2027. Additionally, data from the ongoing BROADEN2 Phase 2b trial of KT-621 in moderate to severe atopic dermatitis is anticipated by mid-2027. The results from these studies have not yet been presented and are expected in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9644716-en) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Kymera Therapeutics (KYMR.US)](https://longbridge.com/zh-HK/quote/KYMR.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)

## 相關資訊與研究

- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-HK/news/278556054.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/zh-HK/news/278778570.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/zh-HK/news/278566951.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/zh-HK/news/278448836.md)
- [Vertex's kidney disease drug meets main goal in late-stage trial](https://longbridge.com/zh-HK/news/278442392.md)